• CDC42 Polarity Controls Intestinal Stem Cell Fate

  2026-09-17

  Zhang and colleagues show that CDC42-dependent epithelial polarity controls the intestinal stem cell to transit-amplifying cell transition through a YAP/TAZ–Ereg–EGFR–mTOR cascade, rather than through canonical Wnt signaling. Their genetic and pharmacological experiments distinguish restoration of crypt proliferation and cell-fate balance from restoration of epithelial polarity.

• 7ACC2: A Monocarboxylate Transporter 1 Inhibitor

  2026-09-16

  7ACC2 is a potent monocarboxylate transporter 1 inhibitor for dissecting lactate flux, mitochondrial pyruvate handling, and tumor radiosensitization. This workflow-oriented guide shows how to connect transport assays with metabolic and immunosuppressive tumor-microenvironment readouts without overinterpreting cross-cell effects.

• PF-573228: A Causal Probe of FAK Signaling

  2026-09-16

  PF-573228 is a potent FAK inhibitor for dissecting how adhesion and matrix stiffness regulate cell behavior. This article translates the LAMB1–FAK–MEK1/2 findings in dentinogenesis into a rigorous assay strategy spanning mechanotransduction, angiogenesis, and cancer biology.

• Perphenazine in Host-Directed Antibacterial Research

  2026-09-15

  Explore how Perphenazine, a dopamine D2 receptor antagonist, can support mechanistic studies spanning neuropharmacology and host-directed antibacterial research. This guide emphasizes receptor-aware assay design, macrophage defense biology, and interpretation of ROS, autophagy, and mitochondrial endpoints.

• CDK4/6–BET Synergy in Pancreatic Cancer Wnt Signaling

  2026-09-15

  The 2025 reference study shows that palbociclib can suppress pancreatic tumor-cell proliferation while paradoxically increasing migration, invasion, and epithelial-to-mesenchymal transition. Its central innovation is the use of BET inhibition to counter this adaptive response through GSK3β-mediated Wnt/β-catenin and TGF-β/Smad pathway regulation, producing stronger antitumor activity in vitro and in an orthotopic model.

• BI 2536: A Better Way to Read PLK1 Inhibition

  2026-09-14

  BI 2536 is a selective PLK1 inhibitor for dissecting mitotic arrest, growth suppression, and apoptosis in cancer models. This article applies a two-axis assay framework to improve interpretation of BI 2536 responses from cultured cells to tumor xenograft models.

• Ruxolitinib JAK1/2 Research Workflows

  2026-09-14

  Build reproducible Ruxolitinib assays by connecting phospho-STAT readouts, progenitor-cell growth, and immune-cell profiling. This practical workflow also adapts the reference study’s multi-readout design without confusing TLR4 biology with direct JAK1/2 inhibition.

• Prestained Protein Marker for LARP1 Blot Workflows

  2026-09-13

  Use a Triple color protein ladder to connect ribosome-fractionation experiments with confident SDS-PAGE sizing, transfer checks, and fluorescent imaging. This workflow shows how an EDTA-free marker supports LARP1 research without overstating what a molecular-weight standard can prove.

• BBB Permeability Modeling with Lysosomal Correction

  2026-09-12

  The 2025 Drug Delivery study developed a high-throughput surrogate blood-brain barrier model by pairing LLC-PK1-MOCK and LLC-PK1-MDR1 cells with bidirectional Transwell transport measurements. Its lysosomal-trapping correction improved interpretation of low-recovery compounds and strengthened the relationship between in vitro permeability and in vivo unbound brain distribution.

• L-Threonine: Metabolism and ALP Assays

  2026-09-11

  L-Threonine is an essential proteinogenic amino acid that links protein biosynthesis with central carbon metabolism. Its role in alkaline phosphatase research is interpretive rather than pharmacological: the cited metal-free nanozyme assay measures ALP through pyrophosphate hydrolysis, not through L-Threonine inhibition.

• PD 173074: FGFR1 and VEGFR2 Research Guide

  2026-09-11

  PD 173074, also written PD-173074, is an ATP-competitive FGFR1 and VEGFR2 research inhibitor with nanomolar reported activity. Its structure, angiogenesis inhibition profile, formulation properties, and model-specific use support cancer research and pathway-dissection workflows.

• Reactive Oxygen Species Assay Kit: ROS Workflow

  2026-09-10

  Build a reproducible live-cell oxidative stress workflow with the Reactive Oxygen Species Assay Kit and its DCFH-DA fluorescent probe. Use it to map ROS changes in redox-active cancer models, validate ROS-responsive nanotherapies, and distinguish fluorescence shifts from genuine cellular injury.

• Exosomal HMGB1 in Lupus Nephritis Endothelial Injury

  2026-09-10

  The reference study identifies podocyte-derived exosomal HMGB1 as a mediator of glomerular endothelial cell injury in lupus nephritis and places TRIM27 downstream of this intercellular signal. Its combination of patient material, cellular perturbation, and mouse-model validation provides a useful framework for dissecting vesicle-mediated mechanisms of proteinuria.

• Primidone (Mysoline): Research Workflows

  2026-09-09

  Primidone (Mysoline) is a versatile research probe for TRPM3 channel inhibition, RIPK1 signaling, and selective biochemical counter-screening. This practical guide connects assay design with ALS and adenomyosis models while emphasizing solvent control, concentration selection, and mechanistic interpretation.

• Leupeptin: Protease Control for TET2 Workflows

  2026-09-09

  Leupeptin provides reversible, competitive control of serine and cysteine proteases across biochemical, autophagy, and viral assays. This guide connects fresh-solution handling and dose-response design with the TET2 metabolite-binding workflow, while clearly separating validated evidence from practical extensions.

812 records 7/55 page Previous Next First page 上5页 678910 下5页 Last page